A pilot study of sunitinib in 15 patients with germline VHL mutations with measurable VHL-associated lesions showed that the drug had manageable toxicity and that 33% (6/18) of RCC lesions showed partial response; however, 0/21 HB lesions showed response [9]. This evidence concerns the gene VHL and renal cell carcinoma.